New data from @ASTRO_org#MRPTS26 presented by @Ganiyani_MD & @RohanGarjeMD reinforce the promise of 177Lu-PSMA-617 in advanced prostate cancer, showing a consistent ability to delay disease progression across randomized trials. Learn More 👇
https://t.co/yrX2pvfmc9
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!
🎶 Wondering how to tackle variant histologies in bladder cancer?
Think of them as music genres—same stage, different openers (neoadj.) and headliners (1st line tx).
🎤 From micropapillary to plasmacytoid—each has a style & strategy.
🎧 Watch here ⬇️
@Uromigos@Dr_Aggen@BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter
@ASCO Guideline Clinical Insights: Systemic therapy in mCRPC, released Sept 4, 2025. Thanks to @rohangarjeMD, Dr. Rahul Parikh, @IrbazRiaz, and Dr. Arsalan Naqvi for their leadership on this article.
@ASCO updates #mCRPC guidelines for the first time in 10 years. Emphasis on individualized care, ongoing ADT, & #BiomarkerTesting. Key trials include MAGNITUDE, TALAPRO-2, and PROpel. @RohanGarjeMD: “This represents a shift toward #PrecisionOncology.” https://t.co/LfoK56eP5R
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
@ASCO Guideline Update
https://t.co/tkHjygAGjP
The updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer (mCRPC). Therapeutic options with demonstrated overall survival benefit include androgen receptor pathway inhibitors (ARPIs), 💊PARP inhibitors, chemotherapy (docetaxel, cabazitaxel), radiopharmaceuticals ☢️(radium-223, 177Lu-PSMA-617), and sipuleucel-T. For patients with BRCA1/2 alterations, ARPI–PARP inhibitor combinations or PARP inhibitor monotherapy are recommended based on prior treatments. Continued androgen-deprivation therapy, early somatic genetic testing, 🦴bone-protective agents for patients with bone metastases, and palliative care are advised. Treatment selection should be guided by prior systemic therapies, although optimal sequencing remains unclear.
@RohanGarjeMD@IrbazRiaz@SyedArsalanN@BryanRumble@TiansterZhang@katy_beckermann@NehaVapiwala@sebastienhotte@arnabguonc@AlanBryce9@lisabodei@DrAndrewLoblaw@HamidEmamekhoo@thomashopemd@M_Hassan_Murad@hongfangliu
Ping
@Silke_Gillessen@AOmlin@nataliagandur@bavilima